298 related articles for article (PubMed ID: 35667922)
1. Induced pluripotent stem cells: a tool for modeling Parkinson's disease.
Bose A; Petsko GA; Studer L
Trends Neurosci; 2022 Aug; 45(8):608-620. PubMed ID: 35667922
[TBL] [Abstract][Full Text] [Related]
2. Modeling Parkinson's Disease Using Patient-specific Induced Pluripotent Stem Cells.
Li H; Jiang H; Zhang B; Feng J
J Parkinsons Dis; 2018; 8(4):479-493. PubMed ID: 30149462
[TBL] [Abstract][Full Text] [Related]
3. Modeling Parkinson's disease with induced pluripotent stem cells harboring α-synuclein mutations.
Singh Dolt K; Hammachi F; Kunath T
Brain Pathol; 2017 Jul; 27(4):545-551. PubMed ID: 28585381
[TBL] [Abstract][Full Text] [Related]
4. Parkinson's disease in a dish - Using stem cells as a molecular tool.
Badger JL; Cordero-Llana O; Hartfield EM; Wade-Martins R
Neuropharmacology; 2014 Jan; 76 Pt A():88-96. PubMed ID: 24035919
[TBL] [Abstract][Full Text] [Related]
5. Using Patient-Derived Induced Pluripotent Stem Cells to Identify Parkinson's Disease-Relevant Phenotypes.
Sison SL; Vermilyea SC; Emborg ME; Ebert AD
Curr Neurol Neurosci Rep; 2018 Oct; 18(12):84. PubMed ID: 30284665
[TBL] [Abstract][Full Text] [Related]
6. Alpha-synuclein dynamics in induced pluripotent stem cell-derived dopaminergic neurons from a Parkinson's disease patient (PARK4) with SNCA triplication.
Fukusumi H; Togo K; Sumida M; Nakamori M; Obika S; Baba K; Shofuda T; Ito D; Okano H; Mochizuki H; Kanemura Y
FEBS Open Bio; 2021 Feb; 11(2):354-366. PubMed ID: 33301617
[TBL] [Abstract][Full Text] [Related]
7. Organoid and pluripotent stem cells in Parkinson's disease modeling: an expert view on their value to drug discovery.
Marotta N; Kim S; Krainc D
Expert Opin Drug Discov; 2020 Apr; 15(4):427-441. PubMed ID: 31899983
[No Abstract] [Full Text] [Related]
8. Modeling Parkinson's disease using induced pluripotent stem cells.
Byers B; Lee HL; Reijo Pera R
Curr Neurol Neurosci Rep; 2012 Jun; 12(3):237-42. PubMed ID: 22538490
[TBL] [Abstract][Full Text] [Related]
9. From 2D to 3D: Development of Monolayer Dopaminergic Neuronal and Midbrain Organoid Cultures for Parkinson's Disease Modeling and Regenerative Therapy.
Yeap YJ; Teddy TJW; Lee MJ; Goh M; Lim KL
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768843
[TBL] [Abstract][Full Text] [Related]
10. Dissecting the non-neuronal cell contribution to Parkinson's disease pathogenesis using induced pluripotent stem cells.
Pons-Espinal M; Blasco-Agell L; Consiglio A
Cell Mol Life Sci; 2021 Mar; 78(5):2081-2094. PubMed ID: 33210214
[TBL] [Abstract][Full Text] [Related]
11. Endosomal dysfunction in iPSC-derived neural cells from Parkinson's disease patients with VPS35 D620N.
Bono K; Hara-Miyauchi C; Sumi S; Oka H; Iguchi Y; Okano HJ
Mol Brain; 2020 Oct; 13(1):137. PubMed ID: 33032646
[TBL] [Abstract][Full Text] [Related]
12. Induced pluripotent stem cell (iPSC)-derived dopaminergic models of Parkinson's disease.
Beevers JE; Caffrey TM; Wade-Martins R
Biochem Soc Trans; 2013 Dec; 41(6):1503-8. PubMed ID: 24256244
[TBL] [Abstract][Full Text] [Related]
13. SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate α-synuclein and are susceptible to oxidative stress.
Byers B; Cord B; Nguyen HN; Schüle B; Fenno L; Lee PC; Deisseroth K; Langston JW; Pera RR; Palmer TD
PLoS One; 2011; 6(11):e26159. PubMed ID: 22110584
[TBL] [Abstract][Full Text] [Related]
14. What we can learn from iPSC-derived cellular models of Parkinson's disease.
Caiazza MC; Lang C; Wade-Martins R
Prog Brain Res; 2020; 252():3-25. PubMed ID: 32247368
[TBL] [Abstract][Full Text] [Related]
15. New Developments in Genetic rat models of Parkinson's Disease.
Creed RB; Goldberg MS
Mov Disord; 2018 May; 33(5):717-729. PubMed ID: 29418019
[TBL] [Abstract][Full Text] [Related]
16. Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons from Familial Parkinson's Disease Patients Display α-Synuclein Pathology and Abnormal Mitochondrial Morphology.
Diao X; Wang F; Becerra-Calixto A; Soto C; Mukherjee A
Cells; 2021 Sep; 10(9):. PubMed ID: 34572052
[TBL] [Abstract][Full Text] [Related]
17. Human Induced Pluripotent Stem Cell Phenotyping and Preclinical Modeling of Familial Parkinson's Disease.
Kim J; Daadi EW; Oh T; Daadi ES; Daadi MM
Genes (Basel); 2022 Oct; 13(11):. PubMed ID: 36360174
[TBL] [Abstract][Full Text] [Related]
18. Single-cell transcriptomics identifies perturbed molecular pathways in midbrain organoids using α-synuclein triplication Parkinson's disease patient-derived iPSCs.
Patikas N; Ansari R; Metzakopian E
Neurosci Res; 2023 Oct; 195():13-28. PubMed ID: 37271312
[TBL] [Abstract][Full Text] [Related]
19. Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and α-Synuclein Accumulation.
Chung SY; Kishinevsky S; Mazzulli JR; Graziotto J; Mrejeru A; Mosharov EV; Puspita L; Valiulahi P; Sulzer D; Milner TA; Taldone T; Krainc D; Studer L; Shim JW
Stem Cell Reports; 2016 Oct; 7(4):664-677. PubMed ID: 27641647
[TBL] [Abstract][Full Text] [Related]
20. Demonstration of brain region-specific neuronal vulnerability in human iPSC-based model of familial Parkinson's disease.
Brazdis RM; Alecu JE; Marsch D; Dahms A; Simmnacher K; Lörentz S; Brendler A; Schneider Y; Marxreiter F; Roybon L; Winner B; Xiang W; Prots I
Hum Mol Genet; 2020 May; 29(7):1180-1191. PubMed ID: 32160287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
